3-Aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: a new class of selective A1 adenosine receptor antagonists.

Radioligand binding assays using bovine cortical membrane preparations and biochemical in vitro studies revealed that various 3-aryl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one (ATBI) derivatives, previously reported by us as ligands of the central benzodiazepine receptor (BzR) (Primofiore, G.; et al. J. Med. Chem. 2000, 43, 96-102), behaved as antagonists at the A1 adenosine receptor (A1AR). Alkylation of the nitrogen at position 10 of the triazinobenzimidazole nucleus conferred selectivity for the A1AR vs the BzR. The most potent ligand of the ATBI series (10-methyl-3-phenyl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one 12) displayed a Ki value of 63 nM at the A1AR without binding appreciably to the adenosine A2A and A3 nor to the benzodiazepine receptor. Pharmacophore-based modeling studies in which 12 was compared against a set of well-established A1AR antagonists suggested that three hydrogen bonding sites (HB1 acceptor, HB2 and HB3 donors) and three lipophilic pockets (L1, L2, and L3) might be available to antagonists within the A1AR binding cleft. According to the proposed pharmacophore scheme, the lead compound 12 engages interactions with the HB2 site (via the N2 nitrogen) as well as with the L2 and L3 sites (through the pendant and the fused benzene rings). The results of these studies prompted the replacement of the methyl with more lipophilic groups at the 10-position (to fill the putative L1 lipophilic pocket) as a strategy to improve A1AR affinity. Among the new compounds synthesized and tested, the 3,10-diphenyl[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-one (23) was characterized by a Ki value of 18 nM which represents a 3.5-fold gain of A1AR affinity compared with the lead 12. A rhodopsin-based model of the bovine adenosine A1AR was built to highlight the binding mode of 23 and two well-known A1AR antagonists (III and VII) and to guide future lead optimization projects. In our docking simulations, 23 receives a hydrogen bond (via the N1 nitrogen) from the side chain of Asn247 (corresponding to the HB1 and HB2 sites) and fills the L1, L2, and L3 lipophilic pockets with the 10-phenyl, 3-phenyl, and fused benzene rings, respectively.

[1]  G. Lu,et al.  Characterization of the A2 adenosine receptor labeled by [3H]NECA in rat striatal membranes. , 1986, Molecular pharmacology.

[2]  A. Tucker,et al.  A1 adenosine receptors. Two amino acids are responsible for species differences in ligand recognition. , 1994, The Journal of biological chemistry.

[3]  Marvin C. Gershengorn,et al.  Interactions between Conserved Residues in Transmembrane Helices 1, 2, and 7 of the Thyrotropin-releasing Hormone Receptor* , 1997, The Journal of Biological Chemistry.

[4]  K. Rothenhäusler,et al.  7-Deaza-2-phenyladenines: structure-activity relationships of potent A1 selective adenosine receptor antagonists. , 1990, Journal of medicinal chemistry.

[5]  K. Jacobson,et al.  Molecular modeling of adenosine receptors. I. The ligand binding site on the A1 receptor. , 1992, Drug design and discovery.

[6]  C. Humblet,et al.  G-Protein coupled receptors: models, mutagenesis, and drug design. , 1998, Journal of medicinal chemistry.

[7]  S. Rivkees,et al.  Identification of the Adenine Binding Site of the Human A1 Adenosine Receptor* , 1999, The Journal of Biological Chemistry.

[8]  J. Baldwin,et al.  Structure and function of receptors coupled to G proteins. , 1994, Current opinion in cell biology.

[9]  G. Liapakis,et al.  Constitutive Activation of the β2 Adrenergic Receptor Alters the Orientation of Its Sixth Membrane-spanning Segment* , 1997, The Journal of Biological Chemistry.

[10]  H. W. Hamilton,et al.  Synthesis and structure-activity relationships of pyrazolo[4,3-d]pyrimidin-7-ones as adenosine receptor antagonists. , 1987, Journal of medicinal chemistry.

[11]  H. V. van Vlijmen,et al.  A model for the antagonist binding site on the adenosine A1 receptor, based on steric, electrostatic, and hydrophobic properties. , 1990, Journal of medicinal chemistry.

[12]  R. G. Browne,et al.  4-Amino[1,2,4]triazolo[4,3-a]quinoxalines. A novel class of potent adenosine receptor antagonists and potential rapid-onset antidepressants. , 1990, Journal of medicinal chemistry.

[13]  F. Allen,et al.  The Cambridge Crystallographic Data Centre: computer-based search, retrieval, analysis and display of information , 1979 .

[14]  I. Kuntz,et al.  Automated docking with grid‐based energy evaluation , 1992 .

[15]  R. Doolittle,et al.  A simple method for displaying the hydropathic character of a protein. , 1982, Journal of molecular biology.

[16]  K. Jacobson,et al.  A role for central A3‐adenosine receptors , 1993, FEBS letters.

[17]  P. Schofield,et al.  A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding. , 1994, The Journal of biological chemistry.

[18]  Brian K. Shoichet,et al.  Molecular docking using shape descriptors , 1992 .

[19]  R. Quinn,et al.  The three binding domain model of adenosine receptors: molecular modeling aspects. , 1992, Journal of medicinal chemistry.

[20]  J. Thornton,et al.  PROCHECK: a program to check the stereochemical quality of protein structures , 1993 .

[21]  J M Blaney,et al.  A geometric approach to macromolecule-ligand interactions. , 1982, Journal of molecular biology.

[22]  R. Quinn,et al.  A computer generated model of adenosine receptors rationalising binding and selectivity of receptor ligands , 1991 .

[23]  M. M. Robison.  Chlorodehydroxylation of Nitrogen Heterocycles with Phenylphosphonic Dichloride , 1958 .

[24]  E. Novellino,et al.  3-Aryl-[1,2,4]triazino[4,3-a]benzimidazol-4(10H)-ones: tricyclic heteroaromatic derivatives as a new class of benzodiazepine receptor ligands. , 2000, Journal of medicinal chemistry.

[25]  Peter A. Kollman,et al.  AMBER, a package of computer programs for applying molecular mechanics, normal mode analysis, molecular dynamics and free energy calculations to simulate the structural and energetic properties of molecules , 1995 .

[26]  G J Williams,et al.  The Protein Data Bank: a computer-based archival file for macromolecular structures. , 1977, Journal of molecular biology.

[27]  Gebhard F. X. Schertler,et al.  Arrangement of rhodopsin transmembrane α-helices , 1997, Nature.

[28]  M. Hatanaka,et al.  Synthetic penicillins. Heterocyclic analogs of ampicillin. Structure-activity relationships. , 1973, Journal of medicinal chemistry.

[29]  K. Jacobson,et al.  Behavioral Effects of Adenosine Receptor stimulation , 1995 .

[30]  K. Jacobson,et al.  A binding site model and structure-activity relationships for the rat A3 adenosine receptor. , 1994, Molecular pharmacology.

[31]  J. Javitch,et al.  A cysteine residue in the third membrane-spanning segment of the human D2 dopamine receptor is exposed in the binding-site crevice. , 1994, Proceedings of the National Academy of Sciences of the United States of America.

[32]  Kenneth A Jacobson,et al.  Molecular architecture of G protein‐coupled receptors , 1996, Drug development research.

[33]  S. Hourani,et al.  Adenosine receptor subtypes. , 1993, Trends in pharmacological sciences.

[34]  K. Jacobson,et al.  Adenosine A1 receptor and ligand molecular modeling , 1993 .

[35]  T. Schwartz,et al.  Locating ligand-binding sites in 7TM receptors by protein engineering. , 1994, Current opinion in biotechnology.

[36]  G. N. Tyurenkova,et al.  SYNTHESIS, STRUCTURES AND TAUTOMERISM OF FORMAZANS CONTAINING A 1-ARYLBENZIMIDAZOL-2-YL RESIDUE , 1980 .

[37]  G. Tsukamoto,et al.  Synthesis of 2-(4-substituted-1-piperazinyl)benzimidazoles as H1-antihistaminic agents. , 1986, Journal of medicinal chemistry.

[38]  H. Weinstein,et al.  Polarity conserved positions in transmembrane domains of G‐protein coupled receptors and bacteriorhodopsin , 1994, FEBS letters.

[39]  E. Meng,et al.  A novel synthesis of xanthines: support for a new binding mode for xanthines with respect to adenosine at adenosine receptors. , 1990, Journal of medicinal chemistry.

[40]  Daniel A. Gschwend,et al.  Orientational sampling and rigid‐body minimization in molecular docking , 1993, Proteins.

[41]  K. Jacobson,et al.  Molecular modeling of adenosine receptors. The ligand binding site on the rat adenosine A2A receptor. , 1994, European journal of pharmacology.

[42]  G A Petsko,et al.  Aromatic-aromatic interaction: a mechanism of protein structure stabilization. , 1985, Science.

[43]  M. Williams,et al.  Adenosine receptors: pharmacology, structure-activity relationships, and therapeutic potential. , 1992, Journal of medicinal chemistry.

[44]  K Konvicka,et al.  A reciprocal mutation supports helix 2 and helix 7 proximity in the gonadotropin-releasing hormone receptor. , 1994, Molecular pharmacology.

[45]  A. Spek,et al.  5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors. , 1999, Journal of medicinal chemistry.

[46]  A. IJzerman,et al.  Influence of the molecular structure of N6-(omega-aminoalkyl)adenosines on adenosine receptor affinity and intrinsic activity. , 1989, European journal of pharmacology.

[47]  K. Kubo,et al.  Adenosine A1 antagonists. 2. Structure-activity relationships on diuretic activities and protective effects against acute renal failure. , 1992, Journal of medicinal chemistry.

[48]  Eamonn F. Healy,et al.  Development and use of quantum mechanical molecular models. 76. AM1: a new general purpose quantum mechanical molecular model , 1985 .

[49]  Hugo Kubinyi,et al.  Similarity and Dissimilarity: A Medicinal Chemist’s View , 2002 .

[50]  A. IJzerman,et al.  1H-imidazo[4,5-c]quinolin-4-amines: novel non-xanthine adenosine antagonists. , 1991, Journal of medicinal chemistry.

[51]  J. Ballesteros,et al.  Residues in the seventh membrane-spanning segment of the dopamine D2 receptor accessible in the binding-site crevice. , 1996, Biochemistry.

[52]  M. L. Connolly.  Analytical molecular surface calculation , 1983 .

[53]  K. Jacobson,et al.  Cloning, expression, and characterization of the unique bovine A1 adenosine receptor. Studies on the ligand binding site by site-directed mutagenesis. , 1992, The Journal of biological chemistry.

[54]  H. Berendsen,et al.  Molecular dynamics with coupling to an external bath , 1984 .

[55]  P. Kollman,et al.  A Second Generation Force Field for the Simulation of Proteins, Nucleic Acids, and Organic Molecules , 1995 .

[56]  A. Dandia,et al.  Synthesis of (1,2,4)Triazino(4,3-a)benzimidazol-4(10H)-ones as Antimicrobial Agents. , 1989 .

[57]  H. Eckert,et al.  Triphosgene, a Crystalline Phosgene Substitute , 1987 .

[58]  K. Jacobson,et al.  Structure-activity relationships of 1,3-dialkylxanthine derivatives at rat A3 adenosine receptors. , 1994, Journal of medicinal chemistry.

[59]  C. Martini,et al.  1,2,4-Triazolo[4,3-a]quinoxalin-1-one: a versatile tool for the synthesis of potent and selective adenosine receptor antagonists. , 2000, Journal of medicinal chemistry.

[60]  M. L. Connolly.  Solvent-accessible surfaces of proteins and nucleic acids. , 1983, Science.

[61]  J. Baldwin,et al.  An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. , 1997, Journal of molecular biology.

[62]  J. Javitch,et al.  Residues in the fifth membrane-spanning segment of the dopamine D2 receptor exposed in the binding-site crevice. , 1995, Biochemistry.

[63]  G. Ghai,et al.  Structure-activity profile of a series of novel triazoloquinazoline adenosine antagonists. , 1988, Journal of medicinal chemistry.

[64]  J. Shimada,et al.  8-Polycycloalkyl-1,3-dipropylxanthines as potent and selective antagonists for A1-adenosine receptors. , 1992, Journal of medicinal chemistry.

[65]  A. A. Pessolano,et al.  Synthesis of Some Substituted Benzimidazolones , 1958 .